Integrating rare genetic variants into pharmacogenetic drug response predictions
Human Genomics, 2018 Background Variability in genes implicated in drug pharmacokinetics or drug response can modulate treatment efficacy or predispose to adverse drug reactions.
Magnus Ingelman-Sundberg +3 more
doaj +1 more source
Topoisomerase 1 Promoter Variants and Benefit from Irinotecan in Metastatic Colorectal Cancer Patients [PDF]
, 2016 Objective: Topoisomerase 1 (topo-1) is an important target for the treatment of metastatic colorectal cancer (CRC). The aim of the present study was to evaluate the correlation between topo-1 single-nucleotide polymorphisms (SNPs) and clinical outcome in
Crea, F. +11 more
core +1 more source
miRNAs as Key Players in the Management of Cutaneous Melanoma
Cells, 2020 The number of treatment options for melanoma patients has grown in the past few years, leading to considerable improvements in both overall and progression-free survival.
Celeste Lorusso +4 more
doaj +1 more source
Prospective study of a molecular selection profile for RAS wild type colorectal cancer patients receiving irinotecan-cetuximab [PDF]
, 2015 Background: The aim of our study was to evaluate whether a panel of biomarkers, prospectively analysed might be able to predict patients' clinical outcome more accurately than RAS status alone.
Abouelkhair, KM +10 more
core +3 more sources
Pharmacogenetics of thiopurines
Cancer Drug Resistance, 2019 Polychemotherapeutic protocols for the treatment of pediatric acute lymphoblastic leukemia (ALL) always include thiopurines. Specific approaches vary in terms of drugs, dosages and combinations. Such therapeutic schemes, including risk-adapted intensity, have been extremely successful for children with ALL who have reached an outstanding 5-year ...
Raffaella Franca +6 more
openaire +4 more sources
PON1 status does not influence cholinesterase activity in Egyptian agricultural workers exposed to chlorpyrifos. [PDF]
, 2012 Animal studies have shown that paraoxonase 1 (PON1) genotype can influence susceptibility to the organophosphorus pesticide chlorpyrifos (CPF). However, Monte Carlo analysis suggests that PON1 genotype may not affect CPF-related toxicity at low exposure ...
Bonner, Matthew R +6 more
core +1 more source
Pharmacogenetics of Cannabinoids [PDF]
European Journal of Drug Metabolism and Pharmacokinetics, 2017 Although the application of medical marijuana and cannabinoid drugs is controversial, it is a part of modern-day medicine. The list of diseases in which cannabinoids are promoted as a treatment is constantly expanding. Cases of significant improvement in patients with a very poor prognosis of glioma or epilepsy have already been described. However, the
Oliwia Zakerska-Banaszak +4 more
openaire +3 more sources
Alcohol addiction: a molecular biology perspective. [PDF]
, 2015 Alcohol misuse represents worldwide an important risk factor for death and disability. Excessive alcohol consumption is widely diffused in different ethnicities and alcohol use is part of the lifestyle of both young and old people.
Ferraguti, Giampiero +2 more
core +1 more source
Pharmacogenetics in Psychiatry: An Update on Clinical Usability
Frontiers in Pharmacology, 2020 Using pharmacogenetics in guiding drug therapy experiences a steady increase in uptake, although still leads to discussions as to its clinical use. Psychiatry constitutes a field where pharmacogenomic testing might help in guiding drug therapy.
R. V. van Schaik +3 more
semanticscholar +1 more source
6-thioguanine treatment in inflammatory bowel disease: A critical appraisal by a European 6-TG working party [PDF]
, 2006 Recently, the suggestion to use 6-thioguanine (6-TG) as an alternative thiopurine in patients with inflammatory bowel disease (IBD) has been discarded due to reports about possible (hepato) toxicity. During meetings arranged in Vienna and Prague in 2004,
A. Teml +52 more
core +1 more source